Jasper Therapeutics
Presença
Fusão, aquisição e financiamento envolvendo Jasper Therapeutics.
- Jasper Therapeutics acaba de anunciar uma arrecadação de fundos de 90 milhões de dólares. (publicado em 31 de janeiro de 2023).
Executivos
Veja o organograma con seus 18 executivos principais
Biografias mais buscadas da Jasper Therapeutics
Recentes movimentos de executivos em Jasper Therapeutics
- Thomas Wiggans, ingressou na Companhia como Chairman of the Board (Notícia publicada em 1 de novembro de 2023).
- Bill Lis, Chairman of the Board, deixou a Companhia (Notícia publicada em 1 de novembro de 2023).
- Jeet Mahal antes Chief Operating and Financial Officer, agora é Chief Operating Officer (Notícia publicada em 26 de setembro de 2023).
Clique aqui para ver outras movimentos em Jasper Therapeutics
Criar um alerta
para seguir os movimentos de executivos da Jasper Therapeutics.
Biotecnologia
Jasper Therapeutics possui 2.281 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Jasper Therapeutics
- News Releases | Jasper Therapeutics, Inc
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
- Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
- Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
- Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
- Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
- Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID | Business Wire
- View more press releases Close
Redes sociais sobre Jasper Therapeutics
- Jasper Therapeutics na Wikipedia, Google News e Yahoo Finance
- Jasper Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Anna French 
Ligue para a Jasper Therapeutics em +1 165 ...
